CWP
NBIX icon

Curated Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History

Curated Wealth Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,671
Closed -$368K – 220
2024
Q1 		$368K Buy
+2,671
New +$365K 0.05% 104

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Curated Wealth Partners's NBIX Position: Q2 2026 in Review

Curated Wealth Partners opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 47,715 shares worth $73.8K. The stake represents 0.01% of the portfolio and ranks #647 among its holdings. This is a return to the name: Curated Wealth Partners previously reported a position in NBIX as recently as Q4 2024.

Curated Wealth Partners first reported a position in NBIX in Q3 2023 and has held it in 6 quarters since. The position peaked at $374K in Q4 2023. 154 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Curated Wealth Partners held 47,715 shares of Neurocrine Biosciences worth $73.8K as of Q2 2026.
  • Neurocrine Biosciences was a new Curated Wealth Partners position in Q2 2026.
  • Neurocrine Biosciences made up 0.01% of Curated Wealth Partners's portfolio in Q2 2026, its #647 holding.
  • Curated Wealth Partners first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 6 quarters since.
  • Curated Wealth Partners's Neurocrine Biosciences position peaked at $374K in Q4 2023.
  • 154 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Curated Wealth Partners's 13F filing for Q2 2026, filed 13 Jul 2026.